GB9110808D0 - Aids vaccine and method for its production - Google Patents

Aids vaccine and method for its production

Info

Publication number
GB9110808D0
GB9110808D0 GB919110808A GB9110808A GB9110808D0 GB 9110808 D0 GB9110808 D0 GB 9110808D0 GB 919110808 A GB919110808 A GB 919110808A GB 9110808 A GB9110808 A GB 9110808A GB 9110808 D0 GB9110808 D0 GB 9110808D0
Authority
GB
United Kingdom
Prior art keywords
virus
production
aids vaccine
treating
inactivating agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GB919110808A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hvivo Services Ltd
Original Assignee
Hvivo Services Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hvivo Services Ltd filed Critical Hvivo Services Ltd
Priority to GB919110808A priority Critical patent/GB9110808D0/en
Publication of GB9110808D0 publication Critical patent/GB9110808D0/en
Priority to ES92304422T priority patent/ES2127203T3/es
Priority to EP92304422A priority patent/EP0514199B1/en
Priority to AT92304422T priority patent/ATE172642T1/de
Priority to IN294MA1992 priority patent/IN174080B/en
Priority to DE69227400T priority patent/DE69227400T2/de
Priority to SG1996004956A priority patent/SG49763A1/en
Priority to AU16340/92A priority patent/AU652447B2/en
Priority to BR929201848A priority patent/BR9201848A/pt
Priority to CA002068817A priority patent/CA2068817A1/en
Priority to ZA923607A priority patent/ZA923607B/xx
Priority to NZ24278092A priority patent/NZ242780A/en
Priority to KR1019920008346A priority patent/KR0149182B1/ko
Priority to JP4168187A priority patent/JPH05328967A/ja
Priority to IE155692A priority patent/IE921556A1/en
Priority to US08/729,135 priority patent/US5698432A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16061—Methods of inactivation or attenuation
    • C12N2760/16063—Methods of inactivation or attenuation by chemical treatment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Telephone Function (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
GB919110808A 1991-05-17 1991-05-17 Aids vaccine and method for its production Pending GB9110808D0 (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
GB919110808A GB9110808D0 (en) 1991-05-17 1991-05-17 Aids vaccine and method for its production
CA002068817A CA2068817A1 (en) 1991-05-17 1992-05-15 Vaccines and methods for their production
SG1996004956A SG49763A1 (en) 1991-05-17 1992-05-15 Vaccines and methods for their preparation
BR929201848A BR9201848A (pt) 1991-05-17 1992-05-15 Processo para a preparacao de particuals de virus para vacinas,vacina,e,processo para tratamento ou profilaxia de uma infeccao viral em um mamifero com necessidade dos mesmos
AT92304422T ATE172642T1 (de) 1991-05-17 1992-05-15 Impfstoffe und verfahren zu ihrer herstellung
IN294MA1992 IN174080B (enExample) 1991-05-17 1992-05-15
DE69227400T DE69227400T2 (de) 1991-05-17 1992-05-15 Impfstoffe und Verfahren zu ihrer Herstellung
ES92304422T ES2127203T3 (es) 1991-05-17 1992-05-15 Vacunas y metodos para su produccion.
AU16340/92A AU652447B2 (en) 1991-05-17 1992-05-15 Vaccines and methods for their production
EP92304422A EP0514199B1 (en) 1991-05-17 1992-05-15 Vaccines and methods for their production
JP4168187A JPH05328967A (ja) 1991-05-17 1992-05-18 Ａｉｄｓワクチン及びその製法
ZA923607A ZA923607B (en) 1991-05-17 1992-05-18 Vaccines and methods for their production
NZ24278092A NZ242780A (en) 1991-05-17 1992-05-18 Preparation of virus particles for vaccines involving multistage inactivation procedure
KR1019920008346A KR0149182B1 (ko) 1991-05-17 1992-05-18 백신 및 그의 제조방법
IE155692A IE921556A1 (en) 1991-05-17 1992-07-01 Vaccines and methods for their production
US08/729,135 US5698432A (en) 1991-05-17 1996-10-11 Vaccines and methods for their production

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB919110808A GB9110808D0 (en) 1991-05-17 1991-05-17 Aids vaccine and method for its production

Publications (1)

Publication Number Publication Date
GB9110808D0 true GB9110808D0 (en) 1991-07-10

Family

ID=10695252

Family Applications (1)

Application Number Title Priority Date Filing Date
GB919110808A Pending GB9110808D0 (en) 1991-05-17 1991-05-17 Aids vaccine and method for its production

Country Status (16)

Country Link
US (1) US5698432A (enExample)
EP (1) EP0514199B1 (enExample)
JP (1) JPH05328967A (enExample)
KR (1) KR0149182B1 (enExample)
AT (1) ATE172642T1 (enExample)
AU (1) AU652447B2 (enExample)
BR (1) BR9201848A (enExample)
CA (1) CA2068817A1 (enExample)
DE (1) DE69227400T2 (enExample)
ES (1) ES2127203T3 (enExample)
GB (1) GB9110808D0 (enExample)
IE (1) IE921556A1 (enExample)
IN (1) IN174080B (enExample)
NZ (1) NZ242780A (enExample)
SG (1) SG49763A1 (enExample)
ZA (1) ZA923607B (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69131427T2 (de) * 1991-05-28 1999-11-25 Kabushiki Kaisha Toshiba, Kawasaki Arbeitsvorrichtung
AUPN030794A0 (en) 1994-12-22 1995-01-27 Aruba International Pty Ltd Discontinuous plasma or serum delipidation
DE19520216C2 (de) * 1995-06-01 1997-04-10 Frey Rainer H Vakzine zur Prophylaxe und Therapie von AIDS, und Verfahren zur Herstellung
US20040053208A1 (en) * 1995-08-29 2004-03-18 V. I. TECHNOLOGIES, Inc. Methods to selectively inactivate parasites in biological compositions
US6093564A (en) 1997-10-03 2000-07-25 V.I. Technologies, Inc. Methods and compositions for the selective modification of nucleic acids
US6352695B1 (en) * 1997-10-03 2002-03-05 V.I. Technologies, Inc. Methods and compositions for the selective modification of nucleic acids
US6617100B2 (en) 1998-09-25 2003-09-09 V.I. Technologies, Inc. Solid phase quenching systems
US6403359B1 (en) 1998-09-25 2002-06-11 V. I. TECHNOLOGIES, Inc. Solid phase quenching systems
DE19916085A1 (de) * 1998-10-28 2000-05-04 Sonntag Hans Guenther Verfahren zur Herstellung eines antiviralen Mittels
US6649170B1 (en) * 1999-05-12 2003-11-18 Statens Serum Institut Adjuvant combinations for immunization composition and vaccines
WO2001046390A2 (en) * 1999-12-20 2001-06-28 Agricultural Research Council Method of inactivating microorganisms
US20090017069A1 (en) 2000-06-29 2009-01-15 Lipid Sciences, Inc. SARS Vaccine Compositions and Methods of Making and Using Them
AUPQ846900A0 (en) * 2000-06-29 2000-07-27 Aruba International Pty Ltd A vaccine
US7439052B2 (en) 2000-06-29 2008-10-21 Lipid Sciences Method of making modified immunodeficiency virus particles
US7407662B2 (en) * 2000-06-29 2008-08-05 Lipid Sciences, Inc. Modified viral particles with immunogenic properties and reduced lipid content
US7407663B2 (en) * 2000-06-29 2008-08-05 Lipid Sciences, Inc. Modified immunodeficiency virus particles
AU2002322284A1 (en) 2001-06-25 2003-01-08 Lipid Sciences, Inc. Systems and methods using multiple solvents for the removal of lipids from fluids
US6991727B2 (en) 2001-06-25 2006-01-31 Lipid Sciences, Inc. Hollow fiber contactor systems for removal of lipids from fluids
US20060060520A1 (en) 2001-06-25 2006-03-23 Bomberger David C Systems and methods using a solvent for the removal of lipids from fluids
DE10144906B4 (de) * 2001-09-12 2013-11-28 Novartis Vaccines And Diagnostics Gmbh Verfahren zur großtechnischen Herstellung von Impfstoffen
AU2002258268A1 (en) * 2001-12-07 2003-06-17 Genexine Co., Ltd. Sivmac239 immunogenic plasmids and aids dna vaccine containing the same
US7393826B2 (en) 2003-07-03 2008-07-01 Lipid Sciences, Inc. Methods and apparatus for creating particle derivatives of HDL with reduced lipid content
JP2007527387A (ja) 2003-07-03 2007-09-27 リピッド サイエンシーズ，インコーポレイテッド 脂質含量の低下したｈｄｌの粒子誘導体を製造するための方法及び装置
US8497112B2 (en) * 2007-08-28 2013-07-30 Baxter International Inc. Method for producing viral vaccines
CA2797059A1 (en) * 2010-05-03 2011-11-10 Glaxosmithkline Biologicals S.A. Novel method
PL2855513T3 (pl) 2012-06-01 2017-05-31 Boehringer Ingelheim Vetmedica Gmbh Szczepionka przeciwko wirusowi Schmallenberg (SBV), sposoby wytwarzania i jej zastosowanie
JP6257607B2 (ja) 2012-06-08 2018-01-10 アデュロ バイオテック，インコーポレイテッド 癌免疫療法のための組成物および方法
MX361680B (es) 2012-12-13 2018-12-13 Aduro Biotech Inc Composiciones que comprenden dinucleótidos de purina cíclicos que tienen estereoquímicas definidas y métodos para su preparación y uso.
SG10201708821RA (en) 2013-04-29 2017-12-28 Memorial Sloan Kettering Cancer Center Compositions and methods for altering second messenger signaling
JP2016518140A (ja) 2013-05-03 2016-06-23 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｉ型インターフェロンの環状ジヌクレオチド誘導法
ES2754269T3 (es) 2013-05-18 2020-04-16 Aduro Biotech Inc Composiciones y métodos de activación de la señalización dependiente del "estimulador de los genes de interferón
US9549944B2 (en) 2013-05-18 2017-01-24 Aduro Biotech, Inc. Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling
US10176292B2 (en) 2013-07-31 2019-01-08 Memorial Sloan-Kettering Cancer Center STING crystals and modulators
JP5865942B2 (ja) 2014-04-16 2016-02-17 三菱電機株式会社 内燃機関のシリンダ吸入空気量推定装置および推定方法
CA2979215A1 (en) 2015-03-10 2016-09-15 Aduro Biotech, Inc. Compositions and methods for activating "stimulator of interferon gene"-dependent signalling
WO2018009466A1 (en) 2016-07-05 2018-01-11 Aduro Biotech, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
EP3714039B1 (en) 2017-11-22 2025-03-12 HDL Therapeutics, Inc. Methods for priming fluid circuits of a plasma processing system
AU2018396009A1 (en) 2017-12-28 2020-07-16 Hdl Therapeutics, Inc. Methods for preserving and administering pre-beta high density lipoprotein extracted from human plasma
CN111629751B (zh) 2018-01-22 2025-02-21 美国政府(由卫生和人类服务部的部长所代表) 广泛保护性灭活流感病毒疫苗
US11643641B2 (en) * 2021-03-04 2023-05-09 Malireddy S. Reddy Prevention of viral transmission by naked genetic material

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1617457A1 (de) * 1966-12-16 1972-04-20 Erba Carlo Spa Verfahren zur Stabilisierung von Zubereitungen interferierender Virusprodukte
US4036952A (en) * 1973-02-24 1977-07-19 Bayer Aktiengesellschaft Ethyleneimine inactivated microorganisms
DE2321951C2 (de) * 1973-05-02 1975-05-07 Behringwerke Ag, 3550 Marburg Verfahren zur Herstellung einer Diphtherie-Vaccine
US4086134A (en) * 1973-09-18 1978-04-25 University Of Glasgow Method for preparation of vaccine against feline leukemia
GB1503388A (en) * 1975-07-01 1978-03-08 Inverni Della Beffa Spa Pharmaceutically active complexes and pharmaceutical compositions containing them
US4452734A (en) * 1980-02-11 1984-06-05 Merck & Co., Inc. Herpes subunit vaccine
US4481189A (en) * 1982-04-14 1984-11-06 New York Blood Center Inc. Process for preparing sterilized plasma and plasma derivatives
US4645666A (en) * 1982-06-08 1987-02-24 The Regents Of The University Of California Vaccine for bluetongue disease employing platinum compounds
US4530831A (en) * 1982-11-02 1985-07-23 Akzo N.V. Infectious Bursal Disease vaccine
US4806350A (en) * 1986-04-18 1989-02-21 Norden Laboratories, Inc. Vaccine formulation
EP0250128A3 (en) * 1986-06-18 1988-06-08 American Registry of Pathology Novel virus isolated from patients with aids
DE3707987A1 (de) * 1987-03-12 1988-09-22 Behringwerke Ag Inaktivierung von human immunodeficiency virus (hiv) in proteinhaltigen loesungen durch phenole
GB8906794D0 (en) * 1989-03-23 1989-05-10 Carroll Noel Preparation of vaccines

Also Published As

Publication number Publication date
DE69227400D1 (de) 1998-12-03
EP0514199A2 (en) 1992-11-19
AU652447B2 (en) 1994-08-25
SG49763A1 (en) 1998-06-15
EP0514199A3 (en) 1993-11-10
ZA923607B (en) 1993-02-24
ATE172642T1 (de) 1998-11-15
US5698432A (en) 1997-12-16
ES2127203T3 (es) 1999-04-16
DE69227400T2 (de) 1999-07-01
KR0149182B1 (ko) 1998-10-15
NZ242780A (en) 1994-07-26
BR9201848A (pt) 1993-01-05
JPH05328967A (ja) 1993-12-14
AU1634092A (en) 1992-12-17
CA2068817A1 (en) 1992-11-18
EP0514199B1 (en) 1998-10-28
IE921556A1 (en) 1992-11-18
KR920021162A (ko) 1992-12-18
IN174080B (enExample) 1994-09-10

Similar Documents

Publication Publication Date Title
GB9110808D0 (en) Aids vaccine and method for its production
DE69434820D1 (de) Nukleinsäurevektor, einen solchen vektor enthaltene verbindung und impfstoff zur immunisierung gegen hepatitis
ZA979732B (en) Infectious clones of RNA viruses and vaccines and diagnostic assays derived therof.
PL325338A1 (en) Methods of and compositions for selectivel;y modifying nucleic acids
PT97754A (pt) Processo para a preparacao de composicoes farmaceuticas contendo pelo menos um agente inibidor da poli-(adp-ribose)-polimerase nomeadamente, uma amida aromatica, para o tratamento de infeccoes provocadas por virus
DE3561472D1 (en) Process for the extraction of poly-beta-hydroxybutyrates with a solvent from an aqueous suspension of microorganisms
PT92931A (pt) Metodo para tratar uma celula hospedeira ex-vivo para desordens hiperproliferativas ou infeccoes e respectiva construcao poli-nucleotidica
EP1394259A3 (en) Recombinant infectious non-segmented negative strand RNA virus
DE69935714D1 (de) Anti-virale vektoren
PT871482E (pt) Vesiculovírus recombinantes e suas utilizações
AU580059B2 (en) Vaccine against rabies and preparation process thereof
GR3034278T3 (en) Attenuated measles vaccine virus strain containing specific nucleotide sequence and a method for its absolute identification.
DK0507179T3 (da) Equine herpesvira (EHV), der indeholder fremmed
EP1057889A4 (en) IMPROVED IMMUNOGEN FOR INACTIVATED VACCINE AGAINST INFECTION WITH JAPANESE ENCEPHALITIS VIRUSES AND METHOD FOR THE PRODUCTION THEREOF
EP0326127A3 (en) Infectious bovine rhinotracheitis virus insertion mutants, vaccins containing same, and methods for the production and use of same
ATE179428T1 (de) Verfahren zur herstellung von hepatitis antigenen und impfstoffen
DE60038281D1 (de) Verfahren zur herstellung von optisch aktiven pyridinethanol-derivaten
WO2003093431A3 (en) Ablated slam-dependent entry
ES2048652A1 (es) Procedimientos de amplificacion de genoma para la deteccion e identificacion de secuencias genomicas relacionadas.
ATE132160T1 (de) Verfahren zur reinigung von aussenmembran-protein von haemophilus influenza
ATE121136T1 (de) Effizientes verfahren zur nachweisbaren expression nichtselektierbarer gene.
ES2367245T8 (es) Virus recombinante que expresa adn foráneo que codifica cd80 felino, cd28 felino, ctla-4felino o cd86 felino y usos del mismo.
DK0841954T3 (da) Fremgangsmåde til fremstilling af et virussikkert, terapeutisk, biologisk apparat
ATE124389T1 (de) Verfahren zur herstellung von n-ethylhydroxylamin-hydrochlorid.
DE50104531D1 (de) Verfahren zum Dauerwellen von menschlichen Haaren